Published: Tuesday, April 12, 2016 - 12:30 Combination products represent an important and growing category of therapeutic and diagnostic products under the U.S. Food and Drug Administration’s (FDA) regulatory authority. These products, which combine a drug, device, and/or biological product (referred to as “constituent parts”) with one another, don’t fit into traditional categories for medical products. Combination products come in three basic configurations: Their constituent parts may be physically or chemically combined, co-packaged, or separately distributed with specific labeling that provides instructions for their combined use. The different constituent parts of a combination product can add complexity to the final product. For example, when a medical device is part of the combination product, issues that relate to how the product is used can be as important as the product itself. Human factors engineering, and the closely related field of usability engineering, both study how people interact with technology, to understand how the design of user interfaces for technology affects the quality, experience, and outcomes of that interaction. The questions addressed by human factors studies overlap with those addressed by “medication error” assessments, another area of user-product interaction evaluation commonly applied to drugs. The understanding gained from these evaluations can be applied to the design and review of the user interfaces for FDA-regulated products to ensure their safety and effectiveness. Because the design of a combination product can have a significant effect on whether a given product is safe and effective for its intended use, human factors evaluations are a central consideration for the FDA when it assesses combination products, particularly those that include certain devices. In February 2016, the FDA published draft guidance for industry and FDA staff titled “Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development.” This draft guidance builds on principles articulated in earlier guidances that discuss human factors and medication error considerations for medical devices and drugs. When final, it will represent the FDA’s thinking on when and how combination product manufacturers should perform human factors evaluations for investigational or marketing applications. The draft guidance provides examples of combination products that include devices, and describes recommendations for how to approach human factors studies for them, focusing on key challenges for developers such as: During the comment period on the draft guidance, the FDA is seeking input on the overall guidance, as well as requesting that stakeholders submit examples of combination products in their comments, and address whether they believe human factors studies are needed for them. The agency is also seeking input on what challenges and development risks may arise if such studies are conducted before, in parallel to, or after major clinical studies for combination products. Input from stakeholders will help inform the FDA’s final guidance in this important area. The comment period for this draft guidance closes on May 3, 2016. Watch for more to come from the FDA this year to further enhance transparency and predictability of combination products regulation. The agency is developing additional guidance for combination products, including current good manufacturing practices (cGMP) and a final rule on post-market safety reporting. The FDA also welcome feedback regarding topics related to combination products that you would like it to address. First published March 24, 2016, on FDA Voice. Jill Hartzler Warner is the FDA’s Associate Commissioner for Special Medical Programs. Thinh Nguyen is the FDA’s Director of the Office of Combination Products.
FDA Compliance Addressing Human Factors Relating to Combination Products
FDA seeks comments on new draft guidance
• The timing and sequencing of human factors studies in relation to overall development and study of a combination product
• How human factors studies compare with and relate to other types of clinical studies
• When changes to a combination product call for new human factors studies to be performed
• The role of simulated-use vs. actual-use human factors studies
• What information should be provided to the FDA, and when, to ensure timely feedback for a human factors study
About The Authors
Jill Hartzler Warner
Thinh Nguyen
© 2022 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute, Inc.
